News
AUTL
1.530
-7.83%
-0.130
Analysts Are Bullish on Top Healthcare Stocks: Autolus Therapeutics (AUTL), Wuxi Biologics (Cayman) (WXIBF)
TipRanks · 5d ago
Weekly Report: what happened at AUTL last week (0525-0529)?
Weekly Report · 06/01 09:47
Weekly Report: what happened at AUTL last week (0518-0522)?
Weekly Report · 05/25 09:49
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
Barchart · 05/21 16:10
Autolus Therapeutics Signals Turning Point in Earnings
TipRanks · 05/19 00:01
Toyo Posts Upbeat Q1 Earnings, Joins Brady, Dominion Energy And Other Big Stocks Moving Higher On Monday
Benzinga · 05/18 16:33
Autolus (AUTL) Q1 2026 Earnings Transcript
The Motley Fool · 05/18 13:09
Weekly Report: what happened at AUTL last week (0511-0515)?
Weekly Report · 05/18 09:49
Wells Fargo Remains a Buy on Autolus Therapeutics (AUTL)
TipRanks · 05/15 11:12
Goldman Sachs Sticks to Their Buy Rating for Autolus Therapeutics (AUTL)
TipRanks · 05/15 06:56
Autolus reiterates $120M-$135M 2026 AUCATZYL revenue guidance as it targets 65%-70% peak ALL gross margin
Seeking Alpha · 05/15 00:11
Autolus Therapeutics: Buy Rating Reiterated as Aucatzyl Momentum Builds and Pipeline Advances; $10 Price Target Maintained
TipRanks · 05/14 18:55
Matt Phipps Reiterates Buy on Autolus as Aucatzyl’s Profitability Inflects and Blockbuster Potential Builds on Expanding Indications
TipRanks · 05/14 18:55
Autolus Therapeutics price target raised to $10 from $9 at H.C. Wainwright
TipRanks · 05/14 18:12
Autolus Therapeutics Price Target Raised to $10.00/Share From $9.00 by HC Wainwright & Co.
Dow Jones · 05/14 17:45
Autolus Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 05/14 17:45
HC Wainwright & Co. Maintains Buy on Autolus Therapeutics, Raises Price Target to $10
Benzinga · 05/14 17:35
Autolus Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript
Benzinga · 05/14 13:42
Autolus Therapeutics Sees FY2026 Sales $120.000M-$135.000M vs $130.062M Est
Benzinga · 05/14 12:58
Autolus Therapeutics reports Q1 EPS (27c), consensus (26c)
TipRanks · 05/14 12:45
More
Webull provides a variety of real-time AUTL stock news. You can receive the latest news about AUTOLUS THERAPEUTICS PLC through multiple platforms. This information may help you make smarter investment decisions.
About AUTL
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.